{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:38:10Z","timestamp":1791815890324,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Brains for Brain (B4B) Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jconrel.2017.02.016","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T21:02:16Z","timestamp":1487278936000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A"],"prefix":"10.1016","volume":"253","author":[{"given":"Tilman","family":"Schuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"M\u00fchlstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Yaghootfam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Maksimenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Shipulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-6715","authenticated-orcid":false,"given":"Svetlana","family":"Gelperina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"Gieselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Matzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.02.016_bb0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tins.2011.05.006","article-title":"Clarifying lysosomal storage diseases","volume":"34","author":"Schultz","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12035-008-8022-3","article-title":"The role and metabolism of sulfatide in the nervous system","volume":"37","author":"Eckhardt","year":"2008","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0015","series-title":"Metachromatic Leukodystrophy and Multiple Sulfatase Deficiency: Sulfatide Lipidosis","author":"Kolodny","year":"1989"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic leukodystrophy\u2014an update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0025","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0030","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/TACG.S86760","article-title":"Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa","volume":"9","author":"Su","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0045","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/mt.2008.305","article-title":"Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy","volume":"17","author":"Matzner","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0055","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/hmg\/ddi126","article-title":"Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy","volume":"14","author":"Matzner","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol Med."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/mgme.1999.2894","article-title":"Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models","volume":"68","author":"Brooks","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2013.06.028","article-title":"Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems","volume":"171","author":"Kozlovskaya","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2011.05.010","article-title":"Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier","volume":"154","author":"Wohlfart","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2009.09.003","article-title":"Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters","volume":"74","author":"Gelperina","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10611860903112842","article-title":"Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles","volume":"17","author":"Kurakhmaeva","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0090","first-page":"1","article-title":"Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging","author":"Koffie","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2014.02.013","article-title":"Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles","author":"Voigt","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2006.10.015","article-title":"Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants","volume":"117","author":"Petri","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-3659(98)00030-3","article-title":"Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition","volume":"55","author":"L\u00fcck","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0110","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0115","doi-asserted-by":"crossref","first-page":"e32568","DOI":"10.1371\/journal.pone.0032568","article-title":"Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model","volume":"7","author":"Wagner","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2017.02.016_bb0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0125","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2174\/0929867323666160210130608","article-title":"Role of nanotechnology for enzyme replacement therapy in lysosomal diseases. A focus on Gaucher's disease","volume":"23","author":"Mart\u00edn-Banderas","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/wnan.73","article-title":"New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders","volume":"2","author":"Muro","year":"2010","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2014.06.008","article-title":"Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes","volume":"188","author":"Papademetriou","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0140","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1016\/j.biomaterials.2013.01.069","article-title":"In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors","volume":"34","author":"Papademetriou","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0145","first-page":"518","article-title":"Arylsulfatase A bound to poly(butyl cyanoacrylate) nanoparticles for enzyme replacement therapy - physicochemical evaluation","volume":"69","author":"M\u00fchlstein","year":"2014","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0150","first-page":"549","article-title":"Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI","volume":"68","author":"M\u00fchlstein","year":"2013","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.2042-7158.1979.tb13510.x","article-title":"Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties","volume":"31","author":"Couvreur","year":"1979","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0160","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0378-5173(99)00370-1","article-title":"Desolvation process and surface characterisation of protein nanoparticles","volume":"194","author":"Weber","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0165","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1021\/bi9714924","article-title":"Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis","volume":"37","author":"Lukatela","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0170","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1093\/nar\/14.24.9679","article-title":"Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis","volume":"14","author":"Nakamaye","year":"1986","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0378-1119(88)90023-6","article-title":"Vectors for efficient expression in mammalian fibroblastoid, myeloid and lymphoid cells via transfection or infection","volume":"68","author":"Artelt","year":"1988","journal-title":"Gene"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0180","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1523\/JNEUROSCI.4785-13.2014","article-title":"Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A","volume":"34","author":"B\u00f6ckenhoff","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1042\/bj2970123","article-title":"Four monoclonal antibodies inhibit the recognition of arylsulphatase A by the lysosomal enzyme phosphotransferase","volume":"297","author":"Sommerlade","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0190","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0009-8981(59)90119-6","article-title":"The assay of arylsulphatases A and B in human urine","volume":"4","author":"Baum","year":"1959","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0195","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejpb.2004.04.006","article-title":"Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting","volume":"58","author":"Nobs","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0200","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0205","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","article-title":"Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy","volume":"93","author":"Hess","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0210","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.gt.3301150","article-title":"Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells","volume":"7","author":"Matzner","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0215","article-title":"Albumin nanoparticles for brain delivery: a comparison of chemical versus thermal methods and in vivo behavior","volume":"1840\u20131849","author":"Bergonzi","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0378-5173(02)00542-2","article-title":"Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods","volume":"250","author":"Nobs","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0230","article-title":"Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders","volume":"1\u201317","author":"Salvalaio","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0235","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/jpet.105.097139","article-title":"Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain","volume":"317","author":"Michaelis","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0240","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2009.03.002","article-title":"Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones","volume":"137","author":"Zensi","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0245","series-title":"Enzymersatztherapie der metachromatischen Leukodystrophie: Untersuchungen zur therapeutischen Wirksamkeit rekombinanter humaner Arylsulfatase A und zum transendothelialen \u00dcbertritt \u00fcber die Blut-Hirn-Schranke","author":"Matthes","year":"2010"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0250","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s11051-012-0850-4","article-title":"Effects of temperature, pH, and ionic strength on the adsorption of nanoparticles at liquid\u2014liquid interfaces","volume":"14","author":"Ferdous","year":"2012","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0255","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1039\/C4CS00487F","article-title":"Nanoparticle colloidal stability in cell culture media and impact on cellular interactions","volume":"44","author":"Moore","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0265","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10611860500411043","article-title":"Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats","volume":"13","author":"Ambruosi","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0270","article-title":"Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier","author":"Chen","year":"2011","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0275","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2217\/nnm.10.131","article-title":"Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier","volume":"6","author":"Kulkarni","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0280","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/glycob\/cwp171","article-title":"Site-specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines","volume":"20","author":"Schr\u00f6der","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0285","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/02652049209021219","article-title":"Influence of the surface properties of low contact angle surfactants on the body distribution of C- poly (methyl methacrylate) nanoparticles","volume":"9","author":"Tr\u00f6ster","year":"1992","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0167-4838(99)00069-2","article-title":"Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells","volume":"1432","author":"He","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymthe.2005.07.687","article-title":"Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis","volume":"13","author":"Muro","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0310","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10545-012-9534-6","article-title":"Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor","volume":"36","author":"Papademetriou","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0315","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0320","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rinphs.2012.11.001","article-title":"Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres","volume":"2","author":"Morales-Cruz","year":"2012","journal-title":"Results Pharma. Sci."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0325","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1096\/fj.08-116947","article-title":"Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury","volume":"23","author":"Reddy","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0330","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/IJN.S54750","article-title":"Tissue inhibitor of matrix metalloproteinases-1 loaded poly(lactic-co-glycolic acid) nanoparticles for delivery across the blood-brain barrier","volume":"9","author":"Chaturvedi","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0335","first-page":"1","article-title":"Use of Polylactide-co-glycolide-nanoparticles for lysosomal delivery of a therapeutic enzyme in glycogenosis type II fibroblasts","volume":"14","author":"Tancini","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0340","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/02652040400026442","article-title":"Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method--processing and formulation issues for enhanced entrapment efficiency","volume":"22","author":"Bilati","year":"2005","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0345","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2008.08.021","article-title":"Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB)","volume":"71","author":"Ulbrich","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0350","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the insulin receptor: nanoparticles for drug delivery across the blood\u2013brain barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0355","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ijpharm.2012.07.029","article-title":"Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery","volume":"436","author":"Xia","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2017.02.016_bb0360","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2005.07.013","article-title":"Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier","volume":"108","author":"Costantino","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.02.016_bb0365","doi-asserted-by":"crossref","DOI":"10.2217\/nnm.11.11","article-title":"Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier","author":"Tosi","year":"2011","journal-title":"Nanomedicine"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917300792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917300792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T15:59:09Z","timestamp":1530115149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917300792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":72,"alternative-id":["S0168365917300792"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.02.016","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}